Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from China NT Pharma Group Co., Ltd. ( (HK:1011) ) is now available.
China NT Pharma has disclosed that past financing arrangements involving share pledges and loan agreements with connected parties were not properly treated as notifiable and connected transactions under Hong Kong listing rules. The company’s board only recently identified that these historical transactions, some involving substantial disposals and high percentage ratios, should have been reported and, in certain cases, approved by independent shareholders.
The share pledges granted in favor of Annie Investment, an associate of a substantial shareholder, are now recognized as very substantial disposals and non-exempt connected transactions requiring higher levels of regulatory compliance. Similarly, a series of loans and supplemental agreements with individuals related to a major shareholder are reclassified as partially or non-exempt connected transactions, highlighting governance and compliance lapses that may concern regulators and investors about past oversight.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. is a pharmaceutical company listed on the Hong Kong Stock Exchange, focusing on the development, manufacturing and distribution of pharmaceutical products. The group operates through various subsidiaries, including NT Pharma (Overseas), NT Pharma (Pacific) and NT China, and engages in financing arrangements linked to its broader corporate structure.
Average Trading Volume: 286,048
Technical Sentiment Signal: Sell
Current Market Cap: HK$607.4M
Learn more about 1011 stock on TipRanks’ Stock Analysis page.